H1 Relaunches “Faculty Opinions” as H1 Connect
Online HCP community allows HCPs and researchers access to the latest breakthroughs in medicine and life sciences research.
H1, has launched H1 Connect,1 the former Faculty Opinions, which it acquired in February 2022.2 Users across Life Sciences, Academic Medical Institutions, Research organizations and more access insights from H1 Connect to drive their respective fields forward.
The re-branded initiative includes the expansion of clinical trial and medical research evaluations by leading experts, as well as a bolstered community, to address the following pain points for HCPs:
- Information overload: Medical knowledge is expanding rapidly, and new research findings emerge frequently. It can be difficult for HCPs to keep up with the evolving evidence base and integrate new information into their clinical practice.
- Data fragmentation: Clinical trial data and research findings are often scattered across many databases, journals, and repositories. This fragmentation makes it difficult for researchers and HCPs to locate and integrate relevant data efficiently and effectively, leading to knowledge gaps and missed opportunities for collaboration.
- Translating research to practice: Translating research findings into clinical practice can be a complex process. HCPs need help assessing the applicability and relevance of research to their patient population, considering factors like patient preferences, comorbidities, and healthcare system constraints.
With input from global Key Opinion Leaders (KOLs), H1 Connect is intended to provide HCPs with quick-to-read insights and commentary; knowledge facilitation and exchange; and collaboration among the global healthcare community.
References:
- H1 Relaunches Faculty Opinions as H1 Connect, the Online Community Where HCPs and Researchers Access the Latest Breakthroughs in Medicine and Life Sciences Research. NEW YORK, JULY 11, 2023
- Global Healthcare Data Leader H1 Acquires Faculty Opinions Making the Opinions of Top Scientists on the Latest Scientific Research More Broadly Accessible, New York, NY – Feb. 16, 2022.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
